Financial Statements of

### **BRAIN CANADA FOUNDATION**

Year ended December 31, 2014

Table of Contents

Independent Auditors' Report	
Statement of Financial Position	1
Statement of Operations and Changes in Net Assets	2
Statement of Cash Flows	3
Notes to Financial Statements	4 - 8

Page



KPMG LLP 600 de Maisonneuve Blvd. West Suite 1500 Tour KPMG Montréal (Québec) H3A 0A3 
 Telephone
 (514) 840-2100

 Fax
 (514) 840-2187

 Internet
 www.kpmg.ca

### **INDEPENDENT AUDITORS' REPORT**

To the Board of Directors of Brain Canada Foundation

We have audited the accompanying financial statements of Brain Canada Foundation, which comprise the statement of financial position as at December 31, 2014, the statements of operations and changes in net assets and cash flows for the year then ended, and notes, comprising a summary of significant accounting policies and other explanatory information.

### Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

#### Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Page 2

### Opinion

In our opinion, the financial statements present fairly, in all material respects, the financial position of Brain Canada Foundation as at December 31, 2014, and its results of operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

KPMG LLP.

February 19, 2015 Montréal, Canada

Statement of Financial Position

#### December 31, 2014, with comparative information for 2013

	2014	2013
Assets		
Current assets:		
Cash and cash equivalents Short-term investments	\$ 5,858,866 29,371,628	
Accrued interest receivable	29,371,628	
Accounts receivable	20,000	
	\$ 35,487,887	\$ 33,947,908
Liabilities and Net Assets Current liabilities: Payable to NeuroScience Canada Partnership Current portion of deferred contributions (note 3)	\$ 26,208,159 26,208,159	· · · · ·
Current liabilities: Payable to NeuroScience Canada Partnership	26,208,159	8,937,259
Current liabilities: Payable to NeuroScience Canada Partnership Current portion of deferred contributions (note 3)	26,208,159	8,937,259 10,357,213
Current liabilities: Payable to NeuroScience Canada Partnership Current portion of deferred contributions (note 3) Non-current liabilities:	26,208,159 26,208,159	8,937,259 10,357,213 23,589,158
Current liabilities: Payable to NeuroScience Canada Partnership Current portion of deferred contributions (note 3) Non-current liabilities:	26,208,159 26,208,159 9,278,494	8,937,259 10,357,213 23,589,158
Current liabilities: Payable to NeuroScience Canada Partnership Current portion of deferred contributions (note 3) Non-current liabilities: Deferred contributions (note 3)	26,208,159 26,208,159 9,278,494	8,937,259 10,357,213 23,589,158 33,946,371
Current liabilities: Payable to NeuroScience Canada Partnership Current portion of deferred contributions (note 3) Non-current liabilities: Deferred contributions (note 3) Net assets:	26,208,159 26,208,159 9,278,494 35,486,653	8,937,259 10,357,213 23,589,158 33,946,371

See accompanying notes to financial statements.

On behalf of the Board:

\_\_\_\_\_ Director

\_\_\_\_\_ Director

Statement of Operations and Changes in Net Assets

### Year ended December 31, 2014, with comparative information for 2013

	2014	2013
Revenues:		
Restricted contributions	\$ 9,039,967	\$ 2,776,030
Expenditures: Transfer to NeuroScience Canada Partnership		
for grants and awards (note 4)	9,039,967	2,776,030
Operating expenses	303	304
	9,040,270	2,776,334
Excess of expenditures over revenues	(303)	(304)
Unrestricted net assets, beginning of year	1,537	1,841
Unrestricted net assets, end of year	\$ 1,234	\$ 1,537

See accompanying notes to financial statements.

Statement of Cash Flows

Year ended December 31, 2014, with comparative information for 2013

	2014	2013
Cash provided by (used in):		
Operating:		
Excess of expenditures over revenues Changes in non-cash components of operating working capital:	\$ (303)	\$ (304)
Accrued interest receivable	(215,313)	(22,080)
Accounts receivable	(20,000)	31,510
Payable to NeuroScience Canada Partnership	(1,419,954)	626,030
	(1,655,570)	635,156
Financing:		
Contributions received during the year	12,000,203	12,489,512
Contributions recognized into revenues during the year	(9,039,967)	(2,776,030)
	2,960,236	9,713,482
Investing:		
Net increase in short-term investments	(627,178)	(18,631,163)
Net increase (decrease) in cash and cash equivalents	677,488	(8,282,525)
Cash and cash equivalents, beginning of year	5,181,378	13,463,903
Cash and cash equivalents, end of year	\$ 5,858,866	\$ 5,181,378
Supplemental non-cash information: Accrued interest receivable included in deferred contributions	\$ 237,393	\$ 22,080

See accompanying notes to financial statements.

Notes to Financial Statements

Year ended December 31, 2014

The Brain Canada Foundation (the "Foundation") is a registered charity incorporated on August 30, 1997 under Part II of the *Canada Corporations Act*. It is a public foundation for federal and provincial tax purposes and is not subject to income taxes. On October 7, 2014, the Foundation obtained its articles of continuance under section 211 of the *Canada Not-for-Profit Corporations Act*.

The purpose and goals of the Foundation are to raise funds to foster advances in neuroscience discovery research, opening the way to better health care for those affected by neurological injury and disease.

### 1. Significant accounting policies:

The financial statements have been prepared by management in accordance with Canadian accounting standards for not-for-profit organizations in Part III of the *CPA Canada Handbook*.

(a) Cash and cash equivalents:

Cash and cash equivalents include cash in bank and highly liquid investments with an original maturity of three months or less. As at December 31, 2014 and 2013, there were no cash equivalents.

(b) Short-term investments:

The short-term investments consist of guaranteed investment certificates bearing interest at 1.35% and with maturity dates between January and November 2015. According to the multiyear contribution agreement with the Minister of Health, the Foundation can only invest any excess cash in interest-bearing certificates of deposit or Treasury bills issued by the government.

(c) Revenue recognition:

The Foundation follows the deferral method of accounting for contributions. Externally restricted contributions relating to future period expenses are recognized as revenue in the year in which the related expenses are incurred. All other contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

A contribution of assets other than cash is measured at the fair value at the date of the contribution.

Restricted investment income is recognized as revenue in the year in which the related expenses are recognized. Unrestricted investment income is recognized as revenue when earned.

Notes to Financial Statements (continued)

Year ended December 31, 2014

### 1. Significant accounting policies (continued):

(d) Financial instruments:

Financial instruments are recorded at fair value on initial recognition. Equity instruments that are quoted in an active market are subsequently measured at fair value. All other financial instruments are subsequently recorded at cost or amortized cost, unless management has elected to carry the instruments at fair value. The Foundation has not elected to carry any such financial instruments at fair value.

Financial assets are assessed for impairment on an annual basis at the end of the fiscal year if there are indicators of impairment. If there is an indicator of impairment, the Foundation determines if there is a significant adverse change in the expected amount or timing of future cash flows from the financial asset. If there is a significant adverse change in the expected cash flows, the carrying value of the financial asset is reduced to the highest of the present value of the expected cash flows, the amount that could be realized from selling the financial asset or the amount the Foundation expects to realize by exercising its right to any collateral. If events and circumstances reverse in a future period, an impairment loss will be reversed to the extent of the improvement, not exceeding the initial carrying value.

(e) Related party transactions:

Monetary related party transactions and non-monetary related party transactions that have commercial substance are measured at the exchange amount when they are in the normal course of business, except when the transaction is an exchange of a product or property held for sale in the normal course of operations. Where the transaction is not in the normal course of operations, it is measured at the exchange amount when there is a substantive change in the ownership of the item transferred and there is independent evidence of the exchange amount.

All other related party transactions are measured at the carrying amount.

(f) Use of estimates:

The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the year. Actual results could differ from those estimates.

Notes to Financial Statements (continued)

Year ended December 31, 2014

### 2. Contribution agreement and pledges:

During the year ended December 31, 2012, the Foundation signed a multi-year contribution agreement with the Minister of Health. The purpose of the agreement is to support the establishment of the Canada Brain Research Fund, which will support the very best Canadian neuroscience, in order to improve the health and quality of life of Canadians who suffer from brain disorders. The Minister of Health has agreed to match, dollar for dollar, the funding received from non-governmental sources up to a maximum of \$100,000,000 over a six-year campaign. Any funding that the Foundation fails to match, as defined in the agreement, shall be repayable to the Minister of Health. In addition, the Minister of Health acknowledges and agrees that up to 10% of the funding for each year may be used by the Foundation for operating expenses and for the design of the research program, as defined in the agreement. The agreement expires on March 31, 2017.

In 2012, the Foundation received an amount of \$20,000,000 as an advance from the Minister of Health to cover the twelve-month periods ended March 31, 2012 and 2013.

In 2013, the Foundation received an amount of \$6,747,567 from the Minister of Health that matches, dollar for dollar, the funding received from non-governmental sources between the beginning of the agreement at April 1, 2011 and December 31, 2012.

In 2014, the Foundation received an amount of \$5,404,909 from the Minister of Health that matches, dollar for dollar, the funding received from non-governmental sources in 2013.

In addition to the amounts received from the Minister of Health, the Foundation also received pledges from non-governmental sources. To date, the Foundation has received total pledges for the matching campaign of \$75,423,149. Since the beginning of the agreement at April 1, 2011, a total of \$18,333,269 has been collected, of which \$6,180,793 was collected during 2014. This amount will be matched by the Minister of Health once approved, as defined in the multi-year contribution agreement.

Notes to Financial Statements (continued)

Year ended December 31, 2014

### 3. Deferred contributions:

Deferred contributions related to expenses of future periods represent unspent externally restricted grants and donations for specific programs.

	2014	2013
Balance, beginning of year Contributions received from the Minister of Health Contributions received from non-governmental sources Investment income on contributions	\$ 32,526,417 5,404,909 6,180,793 414,501	\$ 22,812,935 6,747,567 5,404,909 337,036
	12,000,203	12,489,512
Less amount recognized as revenues	(9,039,967)	(2,776,030)
	35,486,653	32,526,417
Less current portion of deferred contributions	(26,208,159)	(8,937,259)
	\$ 9,278,494	\$ 23,589,158

#### 4. Related party transactions:

The Foundation is affiliated with the NeuroScience Canada Partnership ("NeuroScience Canada"), which was established as a philanthropic organization to foster research and knowledge in neuroscience by supporting innovative researchers in Canadian universities and institutes. The activities of the Foundation and NeuroScience Canada are closely coordinated and under common control (see Note 6).

During the year, the Foundation has granted an amount of \$9,039,967 (2013 - \$2,776,030) to NeuroScience Canada to carry out the work supported by their donors.

### 5. Financial risks:

(a) Liquidity risk:

Liquidity risk is the risk that the Foundation will be unable to fulfill its obligations on a timely basis or at a reasonable cost. The Foundation manages its liquidity risk by monitoring its operating requirements. The Foundation prepares budget and cash forecasts to ensure it has sufficient funds to fulfill its obligations.

Notes to Financial Statements (continued)

Year ended December 31, 2014

### 5. Financial risks (continued):

(b) Interest rate risk:

The Foundation is exposed to interest rate risk on its fixed interest rate investment. Fixed-rate instruments subject the Foundation to a fair value risk. However this risk is mitigated by the fact that the short-term investments mature in the short term.

### 6. Subsequent event:

As at January 1, 2015, the Foundation and NeuroScience Canada amalgamated under section 208 of the *Canada Not-for-Profit Corporations Act*. The amalgamated entities will continue under the name Brain Canada Foundation/Fondation Brain Canada.

### 7. Comparative information

Comparative information related to the current portion of the deferred contribution and amounting to \$8,937,259 has been reclassified to conform with the basis of presentation adopted in the current year.